Literature DB >> 19543572

Improving access to care by allowing self-referral to a hepatitis C clinic.

K E Doucette1, V Robson, S Shafran, D Kunimoto.   

Abstract

BACKGROUND: Estimates suggest that more than 250,000 Canadians are infected with hepatitis C virus (HCV), but less than 10% have been treated. Access to specialists in Canada is usually via health care professional (HCP) referral and, therefore, may be a barrier to HCV care. However, clinics that operate in conjunction with the Hepatitis Support Program, Edmonton, Alberta, allow self-referral. It is hypothesized that this improves access to care without increasing inappropriate referrals.
OBJECTIVE: To compare the baseline characteristics and outcomes of HCV patients who self-referred with those who were HCP-referred.
METHODS: Data were collected from the Hepatitis Support Program HCV database and chart reviews.
RESULTS: Between December 17, 2002, and December 31, 2007, 1563 patients were referred including 336 self- (21.5%) and 1227 HCP-referrals (78.5%). Self- and HCP-referred patients were similar in terms of age (mean [+/- SD] 43.0+/-10.3 years versus 43.9+/-10.0 years, respectively; P=0.18), sex (56.8% versus 62.0% [men], respectively; P=0.08) and risk factors for HCV (P=0.3), with 49.7% and 52.6%, respectively, identifying injection drug use as the primary risk factor. The two groups had similar HCV genotype distributions and liver biopsy fibrosis scores with similar treatment rates (31.3% versus 33.2%; P=0.6). Treatment outcomes were excellent (sustained virological response 40.2% for genotype 1, 67% for genotypes 2 and 3) in patients completing therapy and were similar between the two groups.
CONCLUSION: Self-referred patients comprised 21.5% of patients accessing care in the clinic. Self- and HCP-referred patients had similar characteristics, treatment rates and outcomes. Facilitating self referral to an HCV clinic can improve access to care, including risk reduction education and HCV treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19543572      PMCID: PMC2721809          DOI: 10.1155/2009/216903

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  11 in total

Review 1.  Current status of hepatitis C in Canada.

Authors:  S Zou; M Tepper; A Giulivi
Journal:  Can J Public Health       Date:  2000 Jul-Aug

2.  Where have Canada's general practitioners gone?

Authors:  Wayne Kondro
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

3.  Surprisingly small effect of antiviral treatment in patients with hepatitis C.

Authors:  Yngve Falck-Ytter; Hemangi Kale; Kevin D Mullen; Steedman A Sarbah; Lucian Sorescu; Arthur J McCullough
Journal:  Ann Intern Med       Date:  2002-02-19       Impact factor: 25.391

4.  Do specialist self-referral insurance policies improve access to HIV-experienced physicians as a regular source of care?

Authors:  Kevin C Heslin; Ronald M Andersen; Susan L Ettner; Gerald F Kominski; Thomas R Belin; Hal Morgenstern; William E Cunningham
Journal:  Med Care Res Rev       Date:  2005-10       Impact factor: 3.929

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.

Authors:  Ira M Jacobson; Robert S Brown; Bradley Freilich; Nezam Afdhal; Paul Y Kwo; John Santoro; Scott Becker; Adil E Wakil; David Pound; Eliot Godofsky; Robert Strauss; David Bernstein; Steven Flamm; Mary Pat Pauly; Pabak Mukhopadhyay; Louis H Griffel; Clifford A Brass
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

7.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

8.  Management of chronic hepatitis C: consensus guidelines.

Authors:  Morris Sherman; Stephen Shafran; Kelly Burak; Karen Doucette; Winnie Wong; Nigel Girgrah; Eric Yoshida; Eberhard Renner; Philip Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

9.  Family physicians' knowledge and screening of chronic hepatitis and liver cancer.

Authors:  Jeanne M Ferrante; Dock G Winston; Ping-Hsin Chen; Andrew N de la Torre
Journal:  Fam Med       Date:  2008-05       Impact factor: 1.756

10.  Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group.

Authors: 
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

View more
  7 in total

1.  Pay now or pay (more) later: tracking the costs of hepatitis C infection.

Authors:  Robert P Myers; Samuel S Lee
Journal:  Can J Gastroenterol       Date:  2010-12       Impact factor: 3.522

2.  An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.

Authors:  Robert P Myers; Alnoor Ramji; Marc Bilodeau; Stephen Wong; Jordan J Feld
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

3.  Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center.

Authors:  Janice H Jou; Po-Hung Chen; Alison Jazwinski; Iliana Bouneva; Alastair D Smith; Andrew J Muir
Journal:  Dig Dis Sci       Date:  2010-08-04       Impact factor: 3.199

4.  Health programmes and services addressing the prevention and management of infectious diseases in people who inject drugs in Canada: a systematic integrative review.

Authors:  Katrina Bouzanis; Siddharth Joshi; Cynthia Lokker; Sureka Pavalagantharajah; Yun Qiu; Hargun Sidhu; Lawrence Mbuagbaw; Majdi Qutob; Alia Henedi; Mitchell A H Levine; Robin Lennox; Jean-Eric Tarride; Dale Kalina; Elizabeth Alvarez
Journal:  BMJ Open       Date:  2021-09-23       Impact factor: 3.006

Review 5.  Best strategies for global HCV eradication.

Authors:  Liesl M Hagan; Raymond F Schinazi
Journal:  Liver Int       Date:  2013-02       Impact factor: 5.828

6.  Reasons for Nonattendance across the Hepatitis C Disease Course.

Authors:  Gail Butt; Liza McGuinness; Terri Buller-Taylor; Sandi Mitchell
Journal:  ISRN Nurs       Date:  2013-09-11

Review 7.  Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment.

Authors:  Caroline O'Keefe-Markman; Kristina Dawn Lea; Christopher McCabe; Elaine Hyshka; Tania Bubela
Journal:  BMC Public Health       Date:  2020-01-20       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.